Jazz Depreciation vs Capital Expenditures Analysis

JAZZ Stock  USD 120.56  3.20  2.59%   
Jazz Pharmaceuticals financial indicator trend analysis is infinitely more than just investigating Jazz Pharmaceuticals PLC recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Jazz Pharmaceuticals PLC is a good investment. Please check the relationship between Jazz Pharmaceuticals Depreciation and its Capital Expenditures accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Jazz Pharmaceuticals PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

Depreciation vs Capital Expenditures

Depreciation vs Capital Expenditures Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Jazz Pharmaceuticals PLC Depreciation account and Capital Expenditures. At this time, the significance of the direction appears to have almost no relationship.
The correlation between Jazz Pharmaceuticals' Depreciation and Capital Expenditures is 0.15. Overlapping area represents the amount of variation of Depreciation that can explain the historical movement of Capital Expenditures in the same time period over historical financial statements of Jazz Pharmaceuticals PLC, assuming nothing else is changed. The correlation between historical values of Jazz Pharmaceuticals' Depreciation and Capital Expenditures is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Depreciation of Jazz Pharmaceuticals PLC are associated (or correlated) with its Capital Expenditures. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capital Expenditures has no effect on the direction of Depreciation i.e., Jazz Pharmaceuticals' Depreciation and Capital Expenditures go up and down completely randomly.

Correlation Coefficient

0.15
Relationship DirectionPositive 
Relationship StrengthInsignificant

Depreciation

Depreciation indicates how much of Jazz Pharmaceuticals PLC value has been used up. For tax purposes Jazz Pharmaceuticals can deduct the cost of the tangible assets it purchases as business expenses. However, Jazz Pharmaceuticals PLC must depreciate these assets in accordance with IRS rules about how and when the deduction may be taken, and how long it will last. The systematic allocation of the cost of a tangible asset over its useful life.

Capital Expenditures

Capital Expenditures are funds used by Jazz Pharmaceuticals PLC to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Jazz Pharmaceuticals operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.
Most indicators from Jazz Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Jazz Pharmaceuticals PLC current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Jazz Pharmaceuticals PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
At this time, Jazz Pharmaceuticals' Selling General Administrative is fairly stable compared to the past year. Sales General And Administrative To Revenue is likely to rise to 0.39 in 2025, despite the fact that Tax Provision is likely to grow to (159.8 M).
 2022 2023 2024 2025 (projected)
Gross Profit3.1B3.4B3.9B4.1B
Total Revenue3.7B3.8B4.4B4.6B

Jazz Pharmaceuticals fundamental ratios Correlations

0.50.440.480.450.570.440.410.390.440.450.540.490.40.310.440.480.50.550.050.440.320.40.580.450.45
0.50.980.980.920.930.950.890.970.770.970.790.990.90.580.980.70.980.990.080.980.910.950.990.990.96
0.440.980.980.930.850.950.820.990.660.980.780.980.890.531.00.630.970.97-0.050.990.940.970.951.00.92
0.480.980.980.960.860.90.810.960.680.980.830.960.920.540.970.70.990.970.00.970.90.980.970.980.93
0.450.920.930.960.830.820.710.870.650.940.910.880.920.380.90.790.960.910.050.890.790.980.930.920.9
0.570.930.850.860.830.830.940.820.930.850.760.90.840.630.840.810.910.930.380.840.730.840.960.850.96
0.440.950.950.90.820.830.830.960.690.920.630.970.820.450.960.490.890.95-0.090.960.910.870.90.950.88
0.410.890.820.810.710.940.830.830.910.810.580.880.80.760.830.660.850.870.380.830.760.760.890.830.94
0.390.970.990.960.870.820.960.830.640.960.670.980.850.540.990.530.940.96-0.081.00.960.930.920.990.9
0.440.770.660.680.650.930.690.910.640.650.590.750.740.590.650.750.760.780.560.660.510.640.810.670.87
0.450.970.980.980.940.850.920.810.960.650.790.960.930.490.970.640.970.96-0.070.970.920.960.950.980.93
0.540.790.780.830.910.760.630.580.670.590.790.720.830.390.740.90.870.790.120.720.60.850.840.770.78
0.490.990.980.960.880.90.970.880.980.750.960.720.870.560.980.610.960.990.010.990.920.920.960.990.94
0.40.90.890.920.920.840.820.80.850.740.930.830.870.450.870.740.940.90.10.860.750.90.910.890.93
0.310.580.530.540.380.630.450.760.540.590.490.390.560.450.560.510.560.550.420.560.570.470.60.530.59
0.440.981.00.970.90.840.960.830.990.650.970.740.980.870.560.590.960.97-0.081.00.950.940.941.00.91
0.480.70.630.70.790.810.490.660.530.750.640.90.610.740.510.590.770.690.540.570.420.730.780.620.78
0.50.980.970.990.960.910.890.850.940.760.970.870.960.940.560.960.770.970.10.950.860.970.980.970.96
0.550.990.970.970.910.930.950.870.960.780.960.790.990.90.550.970.690.970.050.970.880.930.990.980.95
0.050.08-0.050.00.050.38-0.090.38-0.080.56-0.070.120.010.10.42-0.080.540.10.05-0.08-0.180.030.16-0.060.27
0.440.980.990.970.890.840.960.831.00.660.970.720.990.860.561.00.570.950.97-0.080.950.930.941.00.91
0.320.910.940.90.790.730.910.760.960.510.920.60.920.750.570.950.420.860.88-0.180.950.880.840.940.81
0.40.950.970.980.980.840.870.760.930.640.960.850.920.90.470.940.730.970.930.030.930.880.940.960.92
0.580.990.950.970.930.960.90.890.920.810.950.840.960.910.60.940.780.980.990.160.940.840.940.950.97
0.450.991.00.980.920.850.950.830.990.670.980.770.990.890.531.00.620.970.98-0.061.00.940.960.950.92
0.450.960.920.930.90.960.880.940.90.870.930.780.940.930.590.910.780.960.950.270.910.810.920.970.92
Click cells to compare fundamentals

Jazz Pharmaceuticals Account Relationship Matchups

Jazz Pharmaceuticals fundamental ratios Accounts

202020212022202320242025 (projected)
Common Stock Shares Outstanding56.5M59.7M62.5M72.1M82.9M51.5M
Total Assets6.5B12.3B10.8B11.4B13.1B13.8B
Short Long Term Debt Total2.2B6.1B5.8B5.8B6.7B7.0B
Other Current Liab338.3M650.5M787.3M774.5M890.6M935.2M
Total Current Liabilities653.7M809.3M933.2M1.5B1.8B1.9B
Total Stockholder Equity3.7B4.0B3.1B3.7B4.3B4.5B
Other Liab337.7M233.9M1.4B1.0B1.2B1.3B
Property Plant And Equipment Net257.1M343.4M301.4M235.0M270.2M283.7M
Net Debt1.2B5.5B4.9B4.3B4.9B5.2B
Retained Earnings1.2B830.2M733.6M878.7M1.0B1.1B
Accounts Payable26.9M100.3M90.8M102.8M118.2M124.1M
Cash1.1B591.4M881.5M1.5B1.7B1.8B
Non Current Assets Total3.7B9.7B8.2B8.0B9.2B9.6B
Non Currrent Assets Other25.7M40.8M58.9M69.2M79.6M83.6M
Other Assets415.0M363.9M435.1M171.5M197.2M136.8M
Long Term Debt1.8B6.0B5.7B5.1B5.9B6.2B
Cash And Short Term Investments2.1B591.4M881.5M1.6B1.9B2.0B
Net Receivables396.5M563.4M651.5M705.8M811.7M852.2M
Good Will958.3M1.8B1.7B1.8B2.0B2.1B
Liabilities And Stockholders Equity6.5B12.3B10.8B11.4B13.1B13.8B
Non Current Liabilities Total2.2B7.5B6.8B6.1B7.0B7.4B
Inventory95.4M1.1B714.1M597.0M686.6M720.9M
Other Current Assets214.9M383.8M359.1M506.3M582.2M611.3M
Other Stockholder Equity2.6B3.5B3.5B3.7B4.3B4.5B
Total Liab2.9B8.3B7.7B7.7B8.8B9.2B
Property Plant And Equipment Gross257.1M343.4M301.4M368.3M423.6M444.8M
Total Current Assets2.8B2.6B2.6B3.4B4.0B4.1B
Accumulated Other Comprehensive Income(134.4M)(400.4M)(1.1B)(842.1M)(757.9M)(720.0M)
Intangible Assets2.2B7.2B5.8B5.4B6.2B6.5B
Property Plant Equipment270.9M127.9M343.4M301.4M346.6M363.9M
Current Deferred Revenue2.5M2.1M463K116.1M133.5M140.2M
Short Term Debt260.8M46.8M46.9M624.4M718.1M754.0M
Net Tangible Assets(250.0M)648.7M(5.0B)(4.3B)(3.9B)(3.7B)
Capital Surpluse2.3B2.6B3.5B3.5B4.0B2.2B

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Jazz Stock Analysis

When running Jazz Pharmaceuticals' price analysis, check to measure Jazz Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Jazz Pharmaceuticals is operating at the current time. Most of Jazz Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Jazz Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Jazz Pharmaceuticals' price. Additionally, you may evaluate how the addition of Jazz Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.